Nerve repair device house Orthocell is taking a cautious approach to entering the US market, with a staged approach to ...

Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...

QMines (ASX:QML) has upgraded its Mount Mackenzie gold and silver resource base and raised the bar on its multi-asset production aspirations.

EchoIQ’s heart-failure AI just hit Mayo’s testing track, chasing FDA clearance and a shot at fixing America’s $60bn hospital headache.

Golden Mile Resources (ASX:G88) goes over the first results from RC drilling in Arizona which showed plentiful copper and lead potential.